AAIC25 | Posters & Presentations

Toronto, Canada | 27th - 31st July | Booth 1531

Unveiling Cutting-Edge Alzheimer's & Dementia Research at AAIC 2025: A Sneak Peek at Our Latest Posters

The Alzheimer’s Association International Conference (AAIC) is just around the corner, and we’re incredibly excited to share some of the latest research our team has been working on. This year at AAIC 2025, we are proud to showcase the latest scientific insights derived from our invaluable partnerships and innovative studies. Our contributions provide critical evidence that could help shape the future of CNS drug development, particularly in the vital fields of Alzheimer’s disease and dementia.

Our presentations delve into key areas, from validating digital speech and language assessments across diverse linguistic backgrounds to exploring the sensitivity of cognitive measures to novel biomarkers. We’re also addressing the crucial psychometric considerations for remote voice assessments and developing new speech-based biomarkers for tracking disease progression.

Get ready to explore how our latest findings are pushing the boundaries of what’s possible in early detection, reliable assessment, and effective trial design for neurodegenerative diseases.

Generalizability of Digital Speech and Language Assessments in MCI/Mild AD Across Four Non-English Languages. First Author: Martina De Lillo, PhD

Poster #107986 Monday, July 28, 2025: 7:30 AM – 4:15 PM

This poster highlights research validating digital speech biomarkers across four non-English languages (Danish, German, Dutch, Spanish) in MCI/mild AD patients. It emphasizes the critical need for confirming clinical interpretability and generalizability for global trials, ensuring these measures are useful and equitable in diverse linguistic contexts.

Sensitivity of Cognitive Outcome Measures to Plasma p-tau217 in Mild Cognitive Impairment in the AI-Mind study. First Author: Alex Kaula, PhD

Poster #108841 Monday, July 28, 2025: 7:30 AM – 4:15 PM EDT

Delve into the clinical validation of CANTAB® cognitive measures by examining their sensitivity to plasma p-tau217 in a Mild Cognitive Impairment (MCI) cohort. This research provides empirical evidence supporting the utility of specific cognitive assessments for screening and early detection of cognitive impairment, and highlighting their potential as reliable and sensitive outcome measures for early-phase interventional trials.

Examining the Stability of Dementia-Relevant Speech Measures in a High-Frequency Picture Description Task Repeated Over 5 Days. First Author: Jessica Robin, PhD

Poster #100541 Monday, July 28, 2025: 7:30 AM – 4:15 PM EDT

Explore critical psychometric considerations for high-frequency, remote voice assessments in preclinical AD. This poster details an investigation into the test-retest reliability of dementia-relevant speech measures over repeated administrations, including the impact of practice and learning effects on longitudinal data. Understand how best to utilize these digital speech biomarkers in order to yield valid and interpretable data for rigorous clinical research.

Development and Validation of Speech-Based Biomarkers for Measuring Clinical Progression in AD Clinical Trials. First Author: Michael Spilka, PhD

Poster #103297 Tuesday, July 29, 2025: 7:30 AM – 4:15 PM EDT

Examine the rigorous clinical validation of a novel speech endpoint designed for use in MCI/AD clinical trials. This poster presents comprehensive data on the development of composite speech biomarkers, demonstrating their ability to objectively track disease progression across the MCI to moderate AD spectrum, with robust test-retest reliability and strong correlations to established clinical endpoints.

[Partner Poster] Establishing Clinical Interpretability of Automatic Speech Assessments in Alzheimer’s Disease. First Author: Jelena Curcic, PhD - Novartis

Poster #97515 Wednesday, July 30, 2025: 7:30 AM – 4:15 PM EDT

This poster addresses the critical need for confirming the clinical interpretability of automatic speech measures, relating them directly to patient-centered outcomes relevant to MCI/AD research. Furthermore, it highlights the scientific imperative for developing and validating speech-based measures in non-English languages, underscoring their generalizability for equitable and effective deployment in global clinical trials.